Related Experiment Video

Updated: May 26, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge

Carlo G Tocchetti1, Gianluca Ragone, Carmela Coppola

  • 1Division of Cardiology, National Cancer Institute, Sen. Pascale Foundation, Naples, Italy. cgtocchetti@iol.it

European Journal of Heart Failure
|January 6, 2012
PubMed

Insights

Trastuzumab improves breast cancer prognosis but can cause heart damage. Research is ongoing to find early markers for trastuzumab cardiotoxicity before ejection fraction decreases.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Trastuzumab targets ErbB2, a receptor overexpressed in 20-30% of breast cancers.
  • While improving breast cancer prognosis, Trastuzumab can cause cardiotoxicity due to ErbB2's role in heart function.
  • The interplay between ErbB2 inhibition and anthracyclines in cardiotoxicity is complex.

Purpose of the Study:

  • To review the pathophysiology of Trastuzumab-induced cardiomyopathy.
  • To discuss the challenges in detecting, monitoring, and managing Trastuzumab cardiotoxicity.
  • To highlight the active research into early, sensitive biomarkers for Trastuzumab toxicity.

Main Methods:

  • Literature review on Trastuzumab cardiotoxicity.
  • Analysis of the pathophysiological mechanisms linking ErbB2 inhibition and cardiac dysfunction.
  • Discussion of current clinical challenges and research directions.

Main Results:

  • Trastuzumab cardiotoxicity is a significant concern, linked to ErbB2's myocardial role.
  • Early detection of Trastuzumab cardiotoxicity remains a challenge.
  • Identifying sensitive biomarkers before ejection fraction decline is a key research focus.

Conclusions:

  • Understanding Trastuzumab cardiotoxicity is crucial for patient management.
  • Further research is needed to develop reliable early detection methods for Trastuzumab-induced heart problems.
  • Developing new biomarkers is essential to mitigate Trastuzumab's cardiac side effects.

More Related Videos

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation09:05

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...